ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO702

A Retrospective Analysis of Cardiovascular Disease (CVD) Events in Prevalent Patients With Focal Segmental Glomerulosclerosis (FSGS) in the United States

Session Information

Category: Glomerular Diseases

  • 1303 Glomerular Diseases: Clinical‚ Outcomes‚ and Trials


  • Velez, Juan Carlos Q., Ochsner Medical Center, New Orleans, Louisiana, United States
  • Thakker, Kamlesh M., Travere Therapeutics Inc, San Diego, California, United States
  • Bensink, Mark Eliot, Travere Therapeutics Inc, San Diego, California, United States
  • Lerma, Edgar V., University of Illinois Chicago, Chicago, Illinois, United States
  • Lieblich, Richard M., VJA Consulting, Walnut Creek, California, United States
  • Bunke, Martin C., CM Bunke Consulting, Mt. Pleasant, South Carolina, United States
  • Wang, Kaijun, Travere Therapeutics Inc, San Diego, California, United States
  • Oliveri, David, Genesis Research LLC, Hoboken, New Jersey, United States
  • Rava, Andrew, Genesis Research LLC, Hoboken, New Jersey, United States
  • Amari, Diana T., Genesis Research LLC, Hoboken, New Jersey, United States
  • Cork, David, Genesis Research LLC Newcastle, Newcastle upon Tyne, United Kingdom

FSGS is a histologic pattern of glomerular injury with numerous causes, frequently associated with kidney disease progression and kidney failure. Although CVD events are known to be associated with end stage kidney disease (ESKD), there is a paucity of research examining this relationship in the FSGS population. We assessed the impact of baseline proteinuria and eGFR decline to ESKD on CVD event incidence and all-cause mortality.


A descriptive, retrospective analysis using Optum® de-identified Market Clarity and proprietary Natural Language Processed (NLP) Data (2007-2020). Inclusion criteria: Patients (≥18yo) with ≥2 FSGS ICD-10 codes (N031, N041, N051, N061, N071) and/or ≥2 FSGS NLP terms within 180 days and ≥30 days apart without associated negation terms, >6mo pre-index activity (exclusion: COVID-19). Post-index CVD events included myocardial infarction (MI), ischemic stroke/transient ischemic attack (TIA), unstable angina, congestive heart failure (CHF), percutaneous coronary intervention (PCI), or coronary artery bypass graft (CABG). All-cause mortality included patients with a death date post-index.


Overall (n=7,974), 11.7% of patients with FSGS experienced a CVD event. Post-ESKD, and among patients with higher baseline proteinuria, CVD events and mortality were significantly elevated (p<.001; Table 1).


A significant increase in CVD events and death was associated with elevated proteinuria and progression to ESKD in patients with FSGS. New therapies for FSGS that reduce proteinuria may reduce CVD events and improve overall survival.


  • Commercial Support